BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 16148113)

  • 1. Cysteine-tailed class I-binding peptides bind to CpG adjuvant and enhance primary CTL responses.
    Wettstein PJ; Borson ND; Park JG; McNallan KT; Reed AM
    J Immunol; 2005 Sep; 175(6):3681-9. PubMed ID: 16148113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Priming MHC-I-restricted cytotoxic T lymphocyte responses to exogenous hepatitis B surface antigen is CD4+ T cell dependent.
    Wild J; Grusby MJ; Schirmbeck R; Reimann J
    J Immunol; 1999 Aug; 163(4):1880-7. PubMed ID: 10438922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity.
    Davila E; Celis E
    J Immunol; 2000 Jul; 165(1):539-47. PubMed ID: 10861094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunostimulatory Properties of Lipid Modified CpG Oligonucleotides.
    Yu C; An M; Li M; Liu H
    Mol Pharm; 2017 Aug; 14(8):2815-2823. PubMed ID: 28686452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antigenic epitopes fused to cationic peptide bound to oligonucleotides facilitate Toll-like receptor 9-dependent, but CD4+ T cell help-independent, priming of CD8+ T cells.
    Schirmbeck R; Riedl P; Zurbriggen R; Akira S; Reimann J
    J Immunol; 2003 Nov; 171(10):5198-207. PubMed ID: 14607920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of point mutations in the native simian virus 40 tumor antigen, and in synthetic peptides corresponding to the H-2Db-restricted epitopes, on antigen presentation and recognition by cytotoxic T lymphocyte clones.
    Deckhut AM; Tevethia SS
    J Immunol; 1992 May; 148(10):3012-20. PubMed ID: 1374447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune Responses and Antitumor Effect through Delivering to Antigen Presenting Cells by Optimized Conjugates Consisting of CpG-DNA and Antigenic Peptide.
    Irie H; Morita K; Koizumi M; Mochizuki S
    Bioconjug Chem; 2020 Nov; 31(11):2585-2595. PubMed ID: 33151667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peptide-priming of cytolytic T cell immunity in vivo using beta 2-microglobulin as an adjuvant.
    Rock KL; Fleischacker C; Gamble S
    J Immunol; 1993 Feb; 150(4):1244-52. PubMed ID: 8381832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant activity of CpG oligodeoxynucleotides.
    Klinman DM
    Int Rev Immunol; 2006; 25(3-4):135-54. PubMed ID: 16818369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The synthetic TLR2 agonist BPPcysMPEG leads to efficient cross-priming against co-administered and linked antigens.
    Prajeeth CK; Jirmo AC; Krishnaswamy JK; Ebensen T; Guzman CA; Weiss S; Constabel H; Schmidt RE; Behrens GM
    Eur J Immunol; 2010 May; 40(5):1272-83. PubMed ID: 20213735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide.
    Miconnet I; Koenig S; Speiser D; Krieg A; Guillaume P; Cerottini JC; Romero P
    J Immunol; 2002 Feb; 168(3):1212-8. PubMed ID: 11801657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tyrosinase-Related Protein2 Peptide with Replacement of N-Terminus Residue by Cysteine Binds to H-2K
    Irie H; Morita K; Matsuda M; Koizumi M; Mochizuki S
    Bioconjug Chem; 2023 Feb; 34(2):433-442. PubMed ID: 36708315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. APC stimulated by CpG oligodeoxynucleotide enhance activation of MHC class I-restricted T cells.
    Warren TL; Bhatia SK; Acosta AM; Dahle CE; Ratliff TL; Krieg AM; Weiner GJ
    J Immunol; 2000 Dec; 165(11):6244-51. PubMed ID: 11086059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunostimulatory CpG motifs trigger a T helper-1 immune response to human immunodeficiency virus type-1 (HIV-1) gp 160 envelope proteins.
    Deml L; Schirmbeck R; Reimann J; Wolf H; Wagner R
    Clin Chem Lab Med; 1999 Mar; 37(3):199-204. PubMed ID: 10353461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
    Davila E; Kennedy R; Celis E
    Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Requirement of nucleobase proximal to CpG dinucleotide for immunostimulatory activity of synthetic CpG DNA.
    Yu D; Kandimalla ER; Zhao Q; Bhagat L; Cong Y; Agrawal S
    Bioorg Med Chem; 2003 Feb; 11(3):459-64. PubMed ID: 12517441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and immunostimulatory properties of CpG DNAs containing alkyl-linker substitutions: role of nucleosides in the flanking sequences.
    Yu D; Kandimalla ER; Cong Y; Tang J; Tang JY; Zhao Q; Agrawal S
    J Med Chem; 2002 Sep; 45(20):4540-8. PubMed ID: 12238933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of dendritic cells and induction of T cell responses by HPV 16 L1/E7 chimeric virus-like particles are enhanced by CpG ODN or sorbitol.
    Freyschmidt EJ; Alonso A; Hartmann G; Gissmann L
    Antivir Ther; 2004 Aug; 9(4):479-89. PubMed ID: 15456078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction Sensitive PEG Hydrogels for Codelivery of Antigen and Adjuvant To Induce Potent CTLs.
    Kapadia CH; Tian S; Perry JL; Luft JC; DeSimone JM
    Mol Pharm; 2016 Oct; 13(10):3381-3394. PubMed ID: 27551741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses.
    Schlosser E; Mueller M; Fischer S; Basta S; Busch DH; Gander B; Groettrup M
    Vaccine; 2008 Mar; 26(13):1626-37. PubMed ID: 18295941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.